Novartis' (NVS -0.3%) Lucentis (which brought in $2.4B last year and is licensed for AMD, DME,...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS -0.3%) Lucentis (which brought in $2.4B last year and is licensed for AMD, DME, and RVO) gains EU approval as "the first and only licensed treatment that has been proven to restore vision" in myopic choroidal neovascularization patients. A pivotal trial showed a 14-letter improvement in the first year with a median of two injections. Genentech (RHHBY.OB -0.4%) has rights to the drug in the U.S. (Also: Goldman likes Eylea based on superiority of Lucentis in study)